About Us Medicines & Focus Research & Development Responsibility Investors News & Events Careers Great Science Deep Compassion Real Impact Working together to address addiction, serious mental illness and cancer. Discover Alkermes Featured News November 24, 2021 Alkermes to Take Part in the Fourth Annual Evercore ISI HealthCONx Conference Read more November 19, 2021 Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors Read more November 11, 2021 Alkermes Announces First Subject Dosed in Phase 1 Study of ALKS 1140 for the Treatment of Neurodegenerative and Neurological Disorders Read more See all press releases Responsibility We champion an approach that views patients holistically and with compassion. Working together with stakeholders across the healthcare community, our team is focused on cutting-edge science, developing innovative medicines and patient-focused advocacy to make a real-world impact in the lives of people living with difficult-to-treat conditions. Visit our Responsibility page Driven by Passion Alkermes employees work in the laboratory, in the clinic and in the community, seeking to make a positive impact on the lives of people living with complicated and difficult-to-treat diseases. For many of our employees, this work is also part of their personal mission to help improve outcomes for patients, families and communities. Learn more about our culture COVID-19 Response In response to urgent and unexpected needs created by the COVID-19 pandemic, Alkermes acted quickly to prioritize the safety of our employees and our communities, and adapted our business practices to support uninterrupted supply of, and patient and provider access to, our medicines and development products. Read our response Pipeline Preview We seek to develop treatments that address unmet patient needs in complex and difficult-to-treat diseases in the areas of neuroscience and oncology. Our pipeline is comprised of clinical and preclinical candidates generated from our scientific platforms, including synaptic dysfunction in neuroscience and immune modulation in oncology. View our pipeline Discovery Preclinical Phase 1 Phase 2 Phase 3 Neuroscience ALKS 1140 - Neurology ALKS 2680 - Narcolepsy Oncology Nemvaleukin alfa* - Platinum-Resistant Ovarian Cancer Nemvaleukin alfa - Mucosal Melanoma *In combination with pembrolizumab Neuroscience Oncology Careers We dare for progress every day. We take pride in our unique and compassionate spirit. Our shared mission to make a real impact for others drives our purpose. With collaboration at our core, we believe that anything is possible. Working at Alkermes We are driven by some of the most pressing health issues of our time to help advance innovation in hopes of providing additional treatment options for people living with complex and often difficult-to-treat diseases. Contact Us Terms of Use Privacy Policy Sitemap © 2021 Alkermes. All rights reserved. Close Please review our Privacy Policy. By using our website without changing your cookie settings you agree to our use of Cookies as described in our Privacy Policy. Learn more